Dr. Johnson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana-Farber Cancer Institute
Boston, MA 02215Phone+1 617-632-4790Fax+1 617-632-5786
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
University of ChicagoResidency, Internal Medicine, 1979 - 1982
University of Minnesota Medical SchoolClass of 1979
Certifications & Licensure
MD State Medical License 1983 - 2026
MA State Medical License 1998 - 2025
NH State Medical License 2024 - 2024
IL State Medical License 1980 - 1984- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FASCO) American Society of Clinical Oncologists, 2012
- Super Doctor SuperDoctors.com
Clinical Trials
- Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Start of enrollment: 1994 Mar 01
- High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations Start of enrollment: 2006 Jun 01
- Dasatinib in Advanced Squamous Cell Lung Cancer Start of enrollment: 2011 Sep 01
Publications & Presentations
PubMed
- 280 citationsSpatially organized multicellular immune hubs in human colorectal cancerKarin Pelka, Matan Hofree, Jonathan H. Chen, Siranush Sarkizova, Joshua D. Pirl
Cell. 2021-09-02 - 134 citationsHLA-Specific Antibodies are Risk Factors for Lymphocytic Bronchiolitis and Chronic Lung Allograft DysfunctionAlin Girnita, Rene Duquesnoy, Samuel A. Yousem, Aldo Iacono, Timothy E. Corcoran
American Journal of Transplantation. 2005-01-01 - 28 citationsVolumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.Mizuki Nishino, Suzanne E. Dahlberg, Linnea Fulton, Subba R. Digumarthy, Hiroto Hatabu
Academic Radiology. 2016-03-01
Journal Articles
- Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer PopulationKhanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation
Press Mentions
Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024September 11th, 2024- ‘A Million Data Points’: A 30-Year Long Lung Cancer Study Meets AIApril 6th, 2023
- In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology ProgramSeptember 8th, 2022
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
